AK-FLUOR 10%
LOE Approachingfluorescein
NDAINTRAVENOUSINJECTABLE
Approved
Aug 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
9
Data completeness
3/8 — Basic
AK-FLUOR 10% (fluorescein) is 465 to 490 nm and fluoresces, i. First approved in 2008.
Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AK-FLUOR 10% is an intravenous fluorescein sodium injection used as a diagnostic imaging agent in ophthalmology. The dye is excited by blue light (465–490 nm) and fluoresces at yellowish-green wavelengths (520–530 nm) to visualize retinal and choroidal vasculature during fundus angiography. It enables clinicians to map blood flow patterns and detect vascular abnormalities in the eye.
LOE Approaching
As a mature diagnostic agent approaching loss of exclusivity, the brand team is likely focused on retention and cost-justification rather than growth initiatives.
Mechanism of Action
465 to 490 nm and fluoresces, i.e., emits light at wavelengths of 520 to 530 nm. Thus, the hydrocarbon is excited by blue light and emits light that appears yellowish green. Following intravenous injection of fluorescein sodium in an aqueous solution, the unbound fraction of the fluorescein can be…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (9)
Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
Started Nov 2025
10 enrolled
RetinopathyRetinal Vein OcclusionDiabetic Retinopathy+1 more
A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma
Started May 2022
21 enrolled
Osteosarcoma
Sodium Fluorescein-Guided Resection of Pediatric Neurosurgical Tumors
Started Aug 2021
2 enrolled
Pediatric Neurosurgical Tumors
Comparison of Fluorescein-INtra-VItal Microscopy Versus Conventional Frozen Section Diagnosis for intraOperative Histopathological Evaluation
Started Dec 2020
210 enrolled
Intracranial Tumor
Ultra-wide Fluorescein Angiography in Patients With Central Retinal Vein Occlusion Treated by Afilbercept
Started Jan 2017
65 enrolled
Retinal Vein Occlusion
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.